AstraZeneca Sues FDA On Crestor Generics: Fighting A 'Foregone Conclusion'?
Company is waging the same legal battle Otsuka lost last year, arguing pediatric orphan indication should block approvals of ANDAs.
Company is waging the same legal battle Otsuka lost last year, arguing pediatric orphan indication should block approvals of ANDAs.